Drug Prices
AHA expresses concern regarding recent action taken by three major drug manufacturers – Eli Lilly and Co., Merck and Sanofi – to limit the distribution of certain 340B drugs to our hospital members.
President Trump signed three executive orders aimed at lowering the price of prescription drugs, with actions targeting federally qualified health center insulin and EpiPen discounts; the importation and re-importation of prescription drugs from foreign countries; and drug manufacturer rebates and…
President Trump today signed three executive orders aimed at lowering the price of prescription drugs. The first executive order seeks to pass federally-qualified health center (FQHC) insulin and EpiPen discounts directly to their patients.
On behalf of our nearly 5,000 member hospitals, health systems and other health care organizations, our clinician partners – including more than 270,000 affiliated physicians, 2 million nurses and other caregivers – and the 43,000 health care leaders who belong to our professional membership groups…
Download the Special Bulletin:
CMS Releases Proposed Rule on Medicaid Drug Value-based Purchasing Arrangements
The Campaign for Sustainable Rx Pricing, for which AHA is a founding member, launched a petition and digital ad urging drug companies to suspend their “traditional” summer price hikes, which last year averaged 13%, saying the industry is thriving while Americans are struggling financially.
The AHA urged the Department of Health and Human Services and the Health Resources and Services Administration to provide flexibility in the administration of the 340B Drug Pricing Program to better enable these hospitals to serve their communities during the COVID-19 national emergency.
List prices for branded pharmaceutical products in the United States increased 159% between 2007 and 2018, an average of 9.1% per year, according to a study reported in JAMA.
Four drugs used in hospitals for years increased their prices between 525% and 1,644% after receiving formal approval through the Food and Drug Administration’s Unapproved Drug Initiative, according to an analysis released by Vizient.
The Food and Drug Administration approved the first generic albuterol sulfate inhaler to treat and prevent bronchospasms in patients with asthma or reversible obstructive airway disease.